List of Rezurock drug patents

Rezurock is owned by Kadmon Pharms Llc.

Rezurock contains Belumosudil Mesylate.

Rezurock has a total of 5 drug patents out of which 0 drug patents have expired.

Rezurock was authorised for market use on 16 July, 2021.

Rezurock is available in tablet;oral dosage forms.

Rezurock can be used as for the treatment of chronic graft versus host disease, for the treatment of chronic graft versus hold disease, treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy.

Drug patent challenges can be filed against Rezurock from July, 2025.

The generics of Rezurock are possible to be released after 09 April, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8357693 KADMON PHARMS LLC Pharmacokinetically improved compounds
Oct, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US10183931 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US9815820 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US11311541 KADMON PHARMS LLC Treatment of GVHD
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2026
Orphan Drug Exclusivity (ODE) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: July, 2025

Market Authorisation Date: 16 July, 2021

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in